Tethered thiazolidinone dimers as inhibitors of the bacterial type III secretion system.

Department of Immunology, University of Washington, Seattle, WA 98195, USA.
Bioorganic & medicinal chemistry letters (Impact Factor: 2.65). 02/2009; 19(5):1340-3. DOI: 10.1016/j.bmcl.2009.01.047
Source: PubMed

ABSTRACT Disruption of protein-protein interactions by small molecules is achievable but presents significant hurdles for effective compound design. In earlier work we identified a series of thiazolidinone inhibitors of the bacterial type III secretion system (T3SS) and demonstrated that this scaffold had the potential to be expanded into molecules with broad-spectrum anti-Gram negative activity. We now report on one series of thiazolidinone analogs in which the heterocycle is presented as a dimer at the termini of a series of linkers. Many of these dimers inhibited the T3SS-dependent secretion of a virulence protein at concentrations lower than that of the original monomeric compound identified in our screen.

  • [Show abstract] [Hide abstract]
    ABSTRACT: The development of new anti-bacterial compounds presents a major challenge to modern medicine as bacterial strains resistant to traditional antibiotics are constantly emerging. Type III secretion systems (T3SSs) are essential for virulence mechanisms of many Gram-negative bacterial pathogens and have therefore emerged as an attractive target for small molecule anti-virulence therapeutics. This has led to several high-throughput screens in search for specific chemicals that inhibit the secretion and translocation of bacterial effector proteins. Several classes of small molecules have now been identified from these screens and this review focuses on their discovery and discusses their potential mechanisms of action and prospects for clinical development.
    Medicinal Chemistry Communication 01/2013; 4(1):68-79. · 2.72 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Introduction: Compounds incorporating guanidine moiety have found many practical applications in diverse areas of chemistry, such as nucleophilic organocatalysis, anion recognition and coordination chemistry. Moreover, guanidine functional group is found in natural products, pharmaceuticals and cosmetic ingredients produced by synthetic methods. Thus, knowledge of their biological activities and therapeutic uses is of utmost importance for researchers involved in drug discovery processes. Areas covered: In this review the authors highlight the continued development and therapeutic applications of newly synthesized guanidine-containing compounds including small peptides and peptidomimetics incorporating arginine. The review presents patents and patent applications filed in the years 2008 - 2012 with emphasis placed on new mechanisms of pharmacological action of guanidine derivatives. Expert opinion: While guanidines are often thought of as strong organic bases and compounds hydrophilic in nature, over the last 4 years there has been an enormous increase in discovery of new promising lead structures with guanidine core, suitable for development of potential drugs acting at central nervous system, anti-inflammatory agents, anti-diabetic and chemotherapeutic agents as well as cosmetics.
    Expert Opinion on Therapeutic Patents 04/2013; · 3.53 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: A facile and convenient protocol was developed for the synthesis of 5-arylidene-2-imino-4-thiazolidinones using solid basic catalyst immobilized onto supported ionic liquid-like phase (SILLP) in high yields (80–95%). The X-ray analysis of the representative compound established the Z configuration of the product at the chiral axis.
    Journal of the Iranian Chemical Society 9(1). · 1.47 Impact Factor


Available from